I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Presentation of Cantargia’s report for the second quarter of 2021

August 19th at 3.00 PM CET

CEO Interview

To the interview (In Swedish)

CEO presentation AGM

To the presentation (In Swedish)

CEO interview

To the interview (in Swedish)

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)

Press releases

2021-10-14 (R) Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer

2021-09-30 (R) Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition

2021-09-29 (R) Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer

(R) = Regulatory press releases

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg

CEO Cantargia

Analysis

2021-05-27, Nordea analysis of Cantargia

2021-04-06, Edison analysis of Cantargia

2021-03-10, Edison analysis of Cantargia

2021-02-26, Nordea analysis of Cantargia

Presentations

2021-09-28, Video, Aktiespararna, Aktiedagen, Lund (In Swedish)

2021-09-28, Presentation, Aktiespararna, Aktiedagen, Lund

2021-09-22, Video, ØU Life Science Investor conference 2021

2021-09-22, Presentation, ØU Life Science Investor Konference 2021

© Copyright 2021 · Cantargia AB